
CRBP Stock Forecast & Price Target
CRBP Analyst Ratings
Bulls say
Corbus Pharmaceuticals Holdings Inc. is making significant advancements in its oncology pipeline, marked by an increased patient enrollment and promising preclinical evidence, particularly for CRB-601, which targets TGF activation in cancer cells. The recent data presented at ASCO GU 2025 highlights CRB-701's favorable risk-benefit profile and an overall response rate of approximately 44%, surpassing that of competitive therapies, indicating its potential for superior safety and efficacy. Collectively, these developments support a strong outlook for the company's stock, emphasizing the innovative nature of its product offerings and their potential to address critical unmet medical needs in the oncology space.
Bears say
Corbus Pharmaceuticals is currently facing a negative outlook due to its valuation being perceived as an overreaction to competitive data, particularly from Novo Nordisk's obesity treatment announcements, which may lead to adverse comparisons with its candidate CRB-913. The potential non-achievement of regulatory approvals or delays in the approval timelines for its product pipeline, including CRB-701 and CRB-601, could substantially harm the company's share price. Additionally, concerns regarding safety profiles—particularly related to ocular toxicity in its therapeutic candidate Tivdak—may hinder adoption and, subsequently, revenue generation for the company.
This aggregate rating is based on analysts' research of Corbus Pharmaceuticals Holdings and is not a guaranteed prediction by Public.com or investment advice.
CRBP Analyst Forecast & Price Prediction
Start investing in CRBP
Order type
Buy in
Order amount
Est. shares
0 shares